Abstract
Arbidol, a new antiviral drug, is found to suppress metastases of Lewis' pulmonary carcinoma for various methods of transplantation. The effects of arbidol are compatible with those of the standard interferon inductor poly-I-poly-C.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
R. G. Glushkovet al., Khim.-Farm. Zh., No. 2, 8 (1992).
I. S. Nikolaeva, A. N. Fomina, E. N. Padeiskaya,et al., in: Ninth All-Union Symposium on the Goal-Directed Search for Drugs, Proceedings [in Russian], Riga (1991), p. 37.
Patent application No. 88-00272 PCT INT., Appl. 1990.
F. A. Trofimov, N. G. Tsyshkova, and A. N. Grinev,Khim.-Farm. Zh., No. 11, 25 (1969).
E. L. Gorelik,Cancer Res.,48, 809 (1987).
S. Radel and V. Zikan,Drugs of the Future,10, 215 (1985).
J. E. Tolmadge,Prog. Exp. Tumor Res.,32, 154 (1988).
Author information
Authors and Affiliations
Additional information
Translated fromByulleten' Eksperimental'noi Biologii i Meditsiny, Vol. 118, No 7, pp. 80–81, July, 1994
Rights and permissions
About this article
Cite this article
Fedorovskaya, E.O., Tsyshkova, N.G., Poverennyi, A.M. et al. Antimetastatic effects of arbidol, a new antiviral drug. Bull Exp Biol Med 118, 764–766 (1994). https://doi.org/10.1007/BF02444380
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02444380